NYSE · SERVICES-MEDICAL LABORATORIES · LARGE CAP
Quest Diagnostics Inc. DGX
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY7 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$11.0B
▲ 11.8% vs FY2024
Dividend streak
7 yrs
Raised every year since 2019
EPS · FY25
$8.75
Dividend / sh · FY25
—
Payout · FY25
36%
ROE · FY25
14.2%
Net margin · FY25
9.0%
Dividend coverage
3.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 11.0B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
9 cents of every revenue dollar became profit this year.
Per share
USD 8.75
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 3.1 times — the rest stayed in the company.
Profitability
14.2%
Return on equity, FY2025
ROE
Operating margin14.1%
Net margin9.0%
Return on assets6.1%
Each USD of equity produced 14 cents of profit this year.
Returned to shareholders
USD 724.0M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 353.0M
Net buybacksUSD 371.0M
Share of profit73.0%
Consecutive raises7 years
USD 353.0M in dividends and USD 371.0M in buybacks — 73% of the year's profit went back to shareholders.
Growth
+3.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.7%
+3.2%
+3.9%
+2.8%
Net income
+1.6%
−7.1%
+3.4%
+2.2%
EPS, diluted
+3.2%
−3.5%
+6.0%
+5.3%
Dividend / share
+10.9%
+17.3%
+16.2%
Returned to shareholders
−23.1%
+10.8%
+6.8%
−0.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 16.2B
total assets, end of FY2025
Total assetsUSD 16.2B
EquityUSD 7.2B
CashUSD 420.0M
Gross debtUSD 5.7B
Net debtUSD 5.3B
Current ratio1.04×
Net debt stands at 73% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
11.0
9.9
9.3
9.9
10.8
9.4
7.7
7.5
7.4
7.2
7.5
7.4
7.1
7.4
7.4
7.3
7.5
7.2
6.7
Operating income $B
1.6
1.3
1.3
1.4
2.4
2.0
1.2
1.1
1.2
1.3
1.4
1.0
1.5
1.2
1.0
1.3
1.4
1.2
1.1
EBITDA $B
2.1
1.8
1.7
1.9
2.8
2.3
1.6
1.4
1.4
1.5
1.7
1.3
1.8
1.5
1.3
1.5
1.6
1.5
1.3
Income tax $B
0.3
0.3
0.2
0.3
0.6
0.5
0.2
0.2
0.2
0.4
0.4
0.3
0.5
0.4
0.4
0.4
0.5
0.4
0.4
Net income $B
1.0
0.9
0.9
0.9
2.0
1.4
0.9
0.7
0.8
0.6
0.7
0.6
0.8
0.6
0.5
0.7
0.7
0.6
0.3
EPS, diluted $
8.75
7.69
7.49
7.97
15.55
10.47
6.28
5.29
5.50
4.51
4.87
3.81
5.54
3.46
2.92
4.05
3.87
2.96
1.74
Dividend / sh $
·
·
·
·
·
·
·
·
1.80
1.65
1.52
1.32
1.20
0.81
0.47
0.40
0.40
0.40
0.40
Payout %
36
38
37
32
15
21
33
36
32
35
30
34
22
19
14
10
10
13
23
ROE %
14.2
13.3
14.0
15.3
30.2
23.1
15.8
14.5
16.2
13.9
15.8
13.5
20.9
14.2
12.2
18.0
19.2
16.1
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed